Revenues for the quarter rose 10.3 per cent YoY to Rs 5,485.84 crore compared with Rs 4,972.58 crore in the same quarter last year.
The profit came largely in line with ET NOW poll estimate of Rs 720 crore.
Ebidta rose 4 per cent YoY to Rs 1,226 crore. Ebitda margin came in at 22.2 per cent, the drugmaker said in an analyst presentation. North America revenues rose 2 per cent to $142 million (from $139 million) for the quarter, which the company said was at a multi-quarter high while noting that a steady momentum in core products offset price erosion in the rest of the portfolio.
Global consumer health franchise gained traction, with the segment contributing 7 per cent to overall revenues in H1FY22, Cipla said. Growth in South Africa, Sub-Saharan Africa (SAGA) region stood at 8 per cent in dollar terms. That region contributed 18 per cent of its sales. India, which accounted for 44 per cent of its revenues, saw 16 per cent growth. International markets, which includes emerging markets and Europe, accounted for 15 per cent of revenues and reported 14 per cent growth.
Emerging markets business resumed middle eastern supplies, demonstrated strong DTM performance and contribution from Covid therapy products.
API segment saw 9 per cent degrowth YoY.
MORE TO COME..
